Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
Industry Veteran with Business Development and Transactional Expertise Joins Eiger Board of Directors
Eiger BioPharmaceuticals, Inc. announced the appointment of Paul Truexto its Board of Directors.
Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and pulmonary diseases. Previously he was Founder, President and CEO of Peninsula Pharmaceuticals where he negotiated both of Peninsula's anti-infective product agreements with Shionogi & Co. Ltd. and Takeda Chemical Industries respectively. Peninsula was acquired by Johnson & Johnson in 2005 for US$ 245 million. Previously, Mr. Truex held positions at Versicor (Vicuron), which was acquired by Pfizer for US$ 1.9 billion, and at Eli Lilly. Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.